Lonsurf Hits Phase III OS Target In Gastric Cancer Study
Executive Summary
An improvement in overall survival seen in the Phase III TAGS study and a unique mechanism of action augurs well for Taiho/Servier's Lonsurf gaining gastric cancer as an additional indication, but future competitive pressures are likely to be intense in this therapeutic sector.
You may also be interested in...
Taiho Oncology CEO Tim Whitten: Building Upon Lonsurf, Inqovi
Solid tumor-focused Taiho Oncology teams with hematological cancer specialist Astex under the Otsuka umbrella. Taiho also performs US/Canada commercialization for all three firms.
Keeping Track Of Oncology: US FDA Approves Herceptin Hylecta, Reviews Darolutamide And Pexidartinib
Oncology news and highlights from our US FDA Performance Tracker.
Servier's Shire Oncology Buy Gives Base For US Expansion
With the $2.4bn acquisition of Shire's oncology assets, including Oncaspar and Onivyde, the French drug maker has laid down a marker to become a key player in cancer and sees the US in particular as the land of opportunity.